Alembic Pharmaceuticals receives USFDA Approval for Bimatoprost Ophthalmic Solution, 0.03%.

Alembic Pharmaceuticals Limited has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bimatoprost Ophthalmic Solution, 0.03%. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Lumigan, 0.03% of Allergan Sales, LLC (Allergan). Bimatoprost Ophthalmic Solution, 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Bimatoprost Ophthalmic Solution, 0.03% have an estimated market size of US$ 10 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 90 ANDA approvals (78 final approvals and 12 tentative approvals) from USFDA.

Shares of ALEMBIC PHARMACEUTICALS LTD. was last trading in BSE at Rs.535 as compared to the previous close of Rs. 535.8. The total number of shares traded during the day was 661 in over 60 trades.

The stock hit an intraday high of Rs. 541.15 and intraday low of 533.95. The net turnover during the day was Rs. 354481.

Source : Equity Bulls

Keywords